trials; manufacturing; regulatory approval requirements and
process; the effort and expense necessary for further development of
Kosan's product candidates, including the costs of bortezomib; intellectual
property matters, including Kosan's ability to obtain valid and enforceable
patents covering its product candidates; Kosan's dependence on its
collaboration with Pfizer for development of its motilin agonist product
candidate; Kosan's need for additional financing and Kosan's strategy to
enter into partnering or licensing arrangements. These and other risk
factors are discussed under "Risk Factors" in Kosan's Quarterly Report on
Form 10-Q for the quarter ended September 30, 2007 and other periodic
filings with the SEC. Kosan expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein.
Velcade(R) (bortezomib) is a registered trademark of Millennium
Pharmaceuticals, Inc.
Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.
Selected Financial Information
Condensed Statements of Operations
(in thousands, except per share amounts)
Three Months Ended Year Ended
December 31, December 31,
2007 2006 2007 2006
(unaudited) (unaudited)
Total revenues $5,636 $5,710 $22,707 $13,506
Operating expenses:
Research and development 13,902 8,817 47,283 37,179
General and administrative 2,108 2,090 8,162 7,823
Total operating expenses 16,010 10,907 55,445 45,002
Loss from operations (10,374) (5,197) (32,738) (31,496)
Other income, net 893 638 4,080 2,027
Net loss
'/>"/>
SOURCE Kosan Biosciences Incorporated Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related biology technology :1.
Kosan Announces February 28, 2008 Conference Call and Webcast2.
Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer3.
Kosan Announces Third Quarter 2007 Financial Results4.
Kosan to Reacquire Epothilone Program From Roche5.
Kosan Biosciences to Host Research & Development Day on October 31, 20076.
Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum7.
Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference8.
Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference9.
Wyeth Announces Executive Change in Finance Organization10.
Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market11.
Pharmacopeia Announces Management Team Changes